Optimi HealthTM is developing a Canadian vertically integrated functional mushroom brand that focuses on the health and wellness food markets. The Company also intends to cultivate, extract, process and distribute high quality strains of fungi products at its Facilities located in Princeton, British Columbia.
In addition, the Company received a Research Exemption in January 2021 and applied for a Dealer’s License in November 2020 through its wholly owned subsidiary Optimi Labs relating to the use and scientific research on psilocybin mushrooms and the possession, distribution, sale, laboratory analysis of and research and development in respect of psilocybin.
CORPORATE HIGHLIGHTS
WELL-FUNDED REVENUE PATHWAY
- Recent Initial Public Offering (IPO) oversubscribed raise of $20.7 million.
- Financial investments encompass capital expenditures for facilities, licensing, e-commerce platform buildout, strategic acquisitions, G &A and working capital.
- Agreement with Canadian Premier Supplements (“CPS”), to provide certain co-packaging and production services.
- Laboratory and Services Agreement with Numinus Wellness Inc. to provide certain psychedelic R&D services and testing.
- Supply agreement with North American Reishi Ltd. (“Nammex”) for the initial supply of organic mushroom extract of Chaga, Cordyceps, Lion’s Mane and Turkey Tail until Optimi farm facilities reach full harvest capacity.
- Consulting services agreement with a University of Calgary business incubator for review, design, planning and/or conducting clinical trial studies for future Optimi products.
STRATEGIC BUSINESS ADVANTAGES
- Vertically integrated operation: Cultivation to Consumer (CTC).
- Potential multi-revenue generating assets: e-Commerce, farm and lab facilities.
- International sales and growth opportunities through established B2B relationships.
- Agreement with Numinus (Licensed Dealer) – resulting IP to be owned 100% by Optimi.
- Consulting Agreement with University partner for multiple clinical trials with Optimi proprietary IP.
EXCEPTIONAL CULTIVATION FACILITIES
- In-house Health Canada consulting.
- Received Health Canada Research Exemption on January 13, 2021.
- Submitted Health Canada Dealers License Application for large scale Psilocybin Cultivation.
- Two 10,000 sq. ft. (each) GMP & EU GMP-capable facilities under construction.
- Expansion opportunity: +25 acres permitted & zoned for use.
EXPERIENCED & PASSIONATE TEAM
- Strong Advisory Team supporting all key aspects of the business.
- Experienced management in cultivation, finance, nutraceutical distribution, wholesale, and retail.
- Agreement to work with Canada’s biggest online Direct-To-Consumer (DTC) supplement retailer.
- Experienced Team operates a recently completed, Health Canada approved, cannabis facility on adjacent property.
PREMIUM NUTRACEUTICALS CTC OPPORTUNITY
- Submitted NPN applications for first 7 product offerings.
- Supplement line has been manufactured & tested – launching Q1 2022.
- Early entry into rapidly expanding marketplace, immediate revenue.
- Turn-key influencer marketing programs planned with a strong pipeline of partners.